# NAGLU

## Overview
The NAGLU gene encodes the enzyme N-acetyl-alpha-glucosaminidase, a lysosomal hydrolase critical for the degradation of heparan sulfate, a glycosaminoglycan. This enzyme is categorized as a lysosomal enzyme due to its role in the breakdown and recycling of complex molecules within lysosomes. The NAGLU protein's structure, characterized by a homotrimeric configuration, is essential for its enzymatic activity and stability (Birrane2019Structural). Mutations in the NAGLU gene lead to Sanfilippo syndrome type B, a lysosomal storage disorder marked by the accumulation of heparan sulfate, resulting in severe neurological symptoms (Birrane2019Structural; Clark2019Assessment). Understanding the structure and function of NAGLU is crucial for developing therapeutic strategies for this condition.

## Structure
The NAGLU protein is a human enzyme involved in the degradation of heparan sulfate, and its structure has been elucidated to provide insights into its function and role in Mucopolysaccharidosis IIIB (MPS IIIB). The primary structure of NAGLU consists of a sequence of amino acids encoded by the NAGLU gene. The secondary structure includes an (α/β)8 barrel and helical domains, with the catalytic domain located in domain II (residues 127-465) (Birrane2019Structural).

The tertiary structure of NAGLU reveals a novel homotrimeric configuration, maintained by hydrophobic and electrostatic interactions, primarily through domain II. The active site cleft is situated between domains II and III, with catalytic glutamate residues E316 and E446 positioned at the top of the (α/β)8 barrel structure in domain II (Birrane2019Structural). The quaternary structure is characterized by a symmetric propeller-shaped trimer, stabilized by hydrophobic interactions and hydrogen bonds, with a buried surface area of approximately 500 Å² at the trimer interface (Birrane2019Structural).

NAGLU undergoes post-translational modifications, including glycosylation, with six putative N-glycosylation sites, all of which are occupied (Birrane2019Structural). These structural insights are crucial for understanding the enzyme's function and for developing therapeutic strategies for MPS IIIB.

## Function
The NAGLU gene encodes the enzyme N-acetyl-alpha-glucosaminidase, which plays a critical role in the lysosomal degradation of heparan sulfate, a type of glycosaminoglycan (Prill2019Differential; Xing2022Downregulation). This enzyme is responsible for hydrolyzing the terminal N-acetyl-D-glucosamine residues in N-acetyl-alpha-D-glucosaminides, facilitating the breakdown and recycling of complex molecules within lysosomes (Jokela2017Deleting). Proper function of NAGLU is essential for maintaining cellular homeostasis by preventing the accumulation of partially degraded heparan sulfate, which can lead to cellular dysfunction (Prill2019Differential).

In healthy human cells, NAGLU is one of several key lysosomal enzymes that ensure the efficient turnover of heparan sulfate, thereby preventing its accumulation and the subsequent development of lysosomal storage disorders (Prill2019Differential). The enzyme's activity is crucial for normal cellular function, as it helps maintain the balance of glycosaminoglycans within the cell, supporting various cellular processes and preventing pathological conditions such as lysosomal storage diseases (Xing2022Downregulation). NAGLU's role in these processes underscores its importance in cellular waste management and overall organismal health.

## Clinical Significance
Mutations in the NAGLU gene are responsible for Sanfilippo syndrome type B, also known as mucopolysaccharidosis IIIB (MPS IIIB), a rare autosomal recessive lysosomal storage disorder. This condition is characterized by a deficiency in the enzyme α-N-acetylglucosaminidase, which is crucial for the degradation of heparan sulfate, a type of glycosaminoglycan. The accumulation of heparan sulfate in lysosomes leads to severe neurological symptoms, including developmental delay, progressive mental retardation, and behavioral disturbances (Beesley1998Identification; Birrane2019Structural; Clark2019Assessment).

The clinical presentation of MPS IIIB varies significantly, with symptoms typically appearing between the ages of 1 and 4 years. The disease progresses through stages of developmental delay, severe behavioral problems, and eventually severe dementia and motor function deterioration. Death often occurs in the second or third decade of life (Weber1999Sanfilippo; Birrane2019Structural).

Over 100 mutations in the NAGLU gene have been identified, including missense, nonsense, deletions, and insertions, contributing to the genetic heterogeneity and clinical variability of the disease (Schmidtchen1998NAGLU; Yogalingam2001Molecular). These mutations often affect conserved amino acids, impacting the enzyme's stability and function, leading to lysosomal dysfunction (Birrane2019Structural).

## Interactions
NAGLU (N-acetyl-alpha-glucosaminidase) is involved in several protein interactions that are crucial for its function in cellular processes. In the context of mucopolysaccharidosis IIIB (MPS IIIB), NAGLU depletion in cardiomyoblasts leads to increased phosphorylation of c-Src, which is an upstream event in the activation of the epidermal growth factor receptor (EGFR). This activation is essential for the hypertrophic response observed in these cells, indicating a transitory interaction where c-Src mediates EGFR activation (De2018EGFR). 

In endothelial cells, NAGLU knockdown results in the upregulation of heparin-binding EGF-like growth factor (HB-EGF), which interacts with vascular endothelial growth factor receptor 2 (VEGFR2). This interaction promotes VEGFR2 phosphorylation and activates the VEGFR2/ERK signaling pathway, contributing to lysosomal accumulation and dysfunction, which are implicated in early atherosclerosis (Xing2022Downregulation). 

The structural characterization of NAGLU reveals that it forms a homotrimeric configuration stabilized by hydrophobic and electrostatic interactions. This trimeric assembly is crucial for its enzymatic activity and stability, highlighting the importance of its structural interactions for its function in lysosomal degradation processes (Birrane2019Structural).


## References


[1. (Xing2022Downregulation) Changchang Xing, Zhongyi Jiang, and Yi Wang. Downregulation of naglu in vec increases abnormal accumulation of lysosomes and represents a predictive biomarker in early atherosclerosis. Frontiers in Cell and Developmental Biology, January 2022. URL: http://dx.doi.org/10.3389/fcell.2021.797047, doi:10.3389/fcell.2021.797047. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.797047)

[2. (Birrane2019Structural) Gabriel Birrane, Anne-Laure Dassier, Alla Romashko, Dianna Lundberg, Kevin Holmes, Thomas Cottle, Angela W. Norton, Bohong Zhang, Michael F. Concino, and Muthuraman Meiyappan. Structural characterization of the α-n-acetylglucosaminidase, a key enzyme in the pathogenesis of sanfilippo syndrome b. Journal of Structural Biology, 205(3):65–71, March 2019. URL: http://dx.doi.org/10.1016/j.jsb.2019.02.005, doi:10.1016/j.jsb.2019.02.005. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jsb.2019.02.005)

[3. (Prill2019Differential) Heather Prill, Amanda Luu, Bryan Yip, John Holtzinger, Melanie J. Lo, Terri M. Christianson, Gouri Yogalingam, Mika Aoyagi-Scharber, Jonathan H. LeBowitz, Brett E. Crawford, and Roger Lawrence. Differential uptake of naglu-igf2 and unmodified naglu in cellular models of sanfilippo syndrome type b. Molecular Therapy - Methods &amp; Clinical Development, 14:56–63, September 2019. URL: http://dx.doi.org/10.1016/j.omtm.2019.05.008, doi:10.1016/j.omtm.2019.05.008. This article has 12 citations.](https://doi.org/10.1016/j.omtm.2019.05.008)

[4. (Jokela2017Deleting) Heli Jokela, Janne Hakkarainen, Laura Kätkänaho, Pirjo Pakarinen, Suvi T. Ruohonen, Manuel Tena-Sempere, Fu-Ping Zhang, and Matti Poutanen. Deleting the mouse hsd17b1 gene results in a hypomorphic naglu allele and a phenotype mimicking a lysosomal storage disease. Scientific Reports, November 2017. URL: http://dx.doi.org/10.1038/s41598-017-16618-5, doi:10.1038/s41598-017-16618-5. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-16618-5)

[5. (Schmidtchen1998NAGLU) Artur Schmidtchen, David Greenberg, Hong G. Zhao, Hong Hua Li, Yan Huang, Phuong Tieu, Hui-Zhi Zhao, Samson Cheng, Zhaoyang Zhao, Chester B. Whitley, Paola Di Natale, and Elizabeth F. Neufeld. Naglu mutations underlying sanfilippo syndrome type b. The American Journal of Human Genetics, 62(1):64–69, January 1998. URL: http://dx.doi.org/10.1086/301685, doi:10.1086/301685. This article has 46 citations.](https://doi.org/10.1086/301685)

[6. (Yogalingam2001Molecular) Gouri Yogalingam and John J. Hopwood. Molecular genetics of mucopolysaccharidosis type iiia and iiib: diagnostic, clinical, and biological implications. Human Mutation, 18(4):264–281, October 2001. URL: http://dx.doi.org/10.1002/humu.1189, doi:10.1002/humu.1189. This article has 140 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.1189)

[7. (Weber1999Sanfilippo) Birgit Weber, Xiao-Hui Guo, Wim J Kleijer, Jacques JP van de Kamp, Ben JHM Poorthuis, and John J Hopwood. Sanfilippo type b syndrome (mucopolysaccharidosis iii b): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. European Journal of Human Genetics, 7(1):34–44, January 1999. URL: http://dx.doi.org/10.1038/sj.ejhg.5200242, doi:10.1038/sj.ejhg.5200242. This article has 81 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.ejhg.5200242)

[8. (De2018EGFR) Valeria De Pasquale, Antonio Pezone, Patrizia Sarogni, Alfonso Tramontano, Gabriele Giacomo Schiattarella, Vittorio Enrico Avvedimento, Simona Paladino, and Luigi Michele Pavone. Egfr activation triggers cellular hypertrophy and lysosomal disease in naglu-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis iiib. Cell Death &amp; Disease, January 2018. URL: http://dx.doi.org/10.1038/s41419-017-0187-0, doi:10.1038/s41419-017-0187-0. This article has 23 citations.](https://doi.org/10.1038/s41419-017-0187-0)

[9. (Beesley1998Identification) C E Beesley, E P Young, A Vellodi, and B G Winchester. Identification of 12 novel mutations in the alpha-n-acetylglucosaminidase gene in 14 patients with sanfilippo syndrome type b (mucopolysaccharidosis type iiib). Journal of Medical Genetics, 35(11):910–914, November 1998. URL: http://dx.doi.org/10.1136/jmg.35.11.910, doi:10.1136/jmg.35.11.910. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.35.11.910)

[10. (Clark2019Assessment) Wyatt T. Clark, Laura Kasak, Constantina Bakolitsa, Zhiqiang Hu, Gaia Andreoletti, Giulia Babbi, Yana Bromberg, Rita Casadio, Roland Dunbrack, Lukas Folkman, Colby T. Ford, David Jones, Panagiotis Katsonis, Kunal Kundu, Olivier Lichtarge, Pier L. Martelli, Sean D. Mooney, Conor Nodzak, Lipika R. Pal, Predrag Radivojac, Castrense Savojardo, Xinghua Shi, Yaoqi Zhou, Aneeta Uppal, Qifang Xu, Yizhou Yin, Vikas Pejaver, Meng Wang, Liping Wei, John Moult, Guoying Karen Yu, Steven E. Brenner, and Jonathan H. LeBowitz. Assessment of predicted enzymatic activity of α‐ n ‐acetylglucosaminidase variants of unknown significance for cagi 2016. Human Mutation, 40(9):1519–1529, September 2019. URL: http://dx.doi.org/10.1002/humu.23875, doi:10.1002/humu.23875. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23875)